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Altered cell metabolism is ubiquitous in cancer cells; however, it remains challenging to exploit these alterations for cancer therapy. A new study reveals that metabolic alterations to the urea cycle promote tumor growth but unexpectedly also trigger mutations that mark cancer cells for recognition by immunotherapy.
Cancer cells have altered metabolic demands compared to the normal cells from which they arise. Aberrant proliferation in cancer cells necessitates changes in metabolic fluxes to support increased biosynthesis of nucleotides, proteins, and lipids to generate cell biomass and divide. Since the repertoire of metabolic enzymes in cancer cells is predominantly the same as in their parental cells, altered cancer metabolism is primarily driven by changes in nutrient uptake, altered enzyme expression, and signalingdependent regulation of enzyme activities (Vander Heiden and DeBerardinis, 2017) . Understanding how specific metabolic alterations benefit tumor growth, as well as the liabilities that accompany these alterations, is critical to improve cancer therapy. In this issue of Cell, Lee et al., (2018) observe pervasive changes to the expression of urea cycle enzymes across tumor types and identify an unforeseen genetic consequence that can sensitize these cancers to immunotherapy.
One burgeoning metabolic alteration in cancer is modifications in urea cycle activity. While the classically described urea cycle is active in the liver and kidney where it functions in organismal nitrogen disposal, other tissues express many urea cycle enzymes. Altered expression of these enzymes occurs in cancer-for example, argininosuccinate synthetase 1 (ASS1) expression is decreased in many tumors compared to parental tissues (Delage et al., 2010) . Decreased ASS1 expression enhances cancer cell proliferation by preventing the consumption of aspartate, a substrate of ASS1, allowing it to be diverted into biosynthetic pathways including pyrimidine nucleotide synthesis ( Figure 1A ) (Rabinovich et al., 2015) . Cancer cells with suppressed ASS1 expression form tumors that grow at a faster rate, suggesting that aspartate levels and pyrimidine synthesis can be endogenous metabolic limitations for tumor growth. Indeed, other methods to increase cancer cell aspartate acquisition can also increase tumor growth (GarciaBermudez et al., 2018; Sullivan et al., 2018) , further supporting the hypothesis that adaptations that preserve aspartate are selected for because they confer a proliferative advantage. However, the extent of dysregulated urea cycle enzyme expression across tumor types, and the metabolic consequences of these changes, have not been broadly characterized.
Since the urea cycle has several linear steps, it is possible to modulate urea cycle function by changes in activity at several points in the pathway. In their study, Lee and colleagues measured expression changes of several urea cycle enzymes across a wide range of cancer types. Impressively, cancers typically had at least one, and usually several, alterations to the expression of urea cycle components in the direction that will promote cytosolic aspartate availability and carbamoyl-phosphate production, enabling increased pyrimidine synthesis ( Figure 1A ) (Kim et al., 2017) . Since the specific urea cycle alterations are not uniform across tumor types, the authors aggregated these changes into a urea cycle dysregulation (UCD) score to compare how the net change to the urea cycle, regardless of the specific components affected, can impact tumor growth ( Figure 1B) . In human tumor samples, higher UCD scores correlated with increased proliferation markers, higher tumor grade, and reduced patient survival. These findings argue that changes in the urea cycle, and the metabolic advantage of conserving metabolites for pyrimidine synthesis, is a general feature of cancer.
One outcome of a high UCD score and enhanced pyrimidine synthesis is an increased intracellular ratio of pyrimidine nucleotides to purine nucleotides (Lee et al., 2018) . Since nucleotide imbalance can have many effects on cells, the authors investigated whether this change in nucleotide levels could affect DNA sequence. Upon induction of UCD, a surprising genetic signature emergedincreased purine-to-pyrimidine transversion mutations on the sense strand of UCD-high cells, a phenomenon they termed pyrimidine-rich transversion mutational bias (PTMB) ( Figure 1B) . While the specific biochemical mechanism is unclear, the authors speculate that this effect may be due to over-incorporation of more abundant pyrimidine nucleotides following DNA damage in the unprotected sense strand during transcription. Regardless, PTMB-associated mutations correlate to UCD scores in human tumors and are confirmed by sequence changes at both the mRNA and protein level.
Treatments that activate immune cells to clear cancer cells can improve patient outcomes (Ribas and Wolchok, 2018) . Immune recognition of tumors following immune checkpoint blockade therapy largely relies on neoantigens that arise from mutations in genetically unstable cancer cells, with higher mutation burdens associated with stronger immune responses. Thus, the authors investigated whether patients harboring tumors with high UCD scores and PTMB signatures had improved outcomes with immune checkpoint blockade therapy. Indeed, UCD score and PTMB signature strongly correlated with responses to immunotherapy in melanoma patients. When they generated isogenic tumors that only differed by UCD score in mice, treatment with checkpoint blockade therapy enhanced CD8+ T cell infiltration into UCD-high tumors and caused substantial tumor suppression. Interestingly, the PTMB signature was not correlated with an overt increase in mutation rates, making (A) Directional changes in urea cycle components in cancer, and the resulting increase in availability of aspartate and carbamoyl phosphate for pyrimidine synthesis, promotes cancer cell proliferation. CPS1, carbamoyl-phosphate synthetase 1; OTC, ornithine transcarbamylase; ORNT, ornithine translocase; ASS1, argininosuccinate synthetase 1; ASL, argininosuccinate lyase. Some enzyme/transporter co-substrates were omitted for clarity. (B) Changes in urea cycle components can be aggregated into a urea cycle dysregulation (UCD) score. Changes in UCD score can cause metabolite level changes, leading to purine-to-pyrimidine transversion mutations in the sense strand, increasing the immunogenicity of tumor antigens, thereby affecting sensitivity to immunotherapy. it unclear why the immune system would display enhanced recognition of these cancer cells. One possibility is that the types of mutations caused by PTMB create more effective neoantigens for immune recognition. Indeed, calculating the effects of PTMB alterations on amino acid sequences revealed that purine-topyrimidine transversions in the sense strand more frequently result in conversion of a hydrophilic amino acid into a hydrophobic amino acid. T cells more efficiently recognize epitopes with hydrophobic residues (Chowell et al., 2015) ; thus, Lee and colleagues compared neoantigens on cancer cells differing by UCD score and observed increased hydrophobicity of neopeptides in UCD-high cells, potentially explaining why checkpoint blockade therapy has enhanced activity to control UCD-high tumors. Thus, these results suggest a method to stratify patients that are most likely to benefit from immunotherapy.
While changes in metabolite levels have been well documented to alter gene expression (Schvartzman et al., 2018) , this study is unique in showing that dysregulated metabolite levels can also modify genetics by causing nonrandom somatic mutations. One extension of this idea is that metabolite-driven changes in DNA sequence may not be exclusive to endogenously produced metabolites in tumor cells. It raises the possibility that dietary and/or physiological changes that cause metabolite imbalances could contribute to somatic mutations in normal cells and thereby alter disease risk. It is also possible that cancer cells are particularly vulnerable to the effects of nucleotide imbalance, and thus, dietary interventions might be employed to genetically mark cancer cells for immune recognition. In any case, these findings add another example of the complex ramifications that changes at one biological level can have on the rest of the system, including processes as seemingly disparate as metabolite levels and antigen presentation.
